Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Access barriers and facilitators to implement mass drugs administration strategies for eliminating trachoma and geohelminthiasis in the department of Amazonas, Colombia.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • المصدر:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: San Francisco, CA : Public Library of Science
    • الموضوع:
    • نبذة مختصرة :
      Background: One of the most important pillars of action to achieve the elimination of trachoma and soil-transmitted helminth infections as a public health problem is the mass administration, at regular intervals, of azithromycin and anthielmintics, respectively, to a high proportion of the eligible population in endemic areas.
      Objective: The objective of the study was to identify access barriers and facilitators for achieving coverage goals in the mass drugs administration, azithromycin and albendazole, in the department of Amazonas, Colombia.
      Methodology: Implementation research was used, combining three types of qualitative research methodologies to collect information about access barriers and facilitators already described; These were individual and group interviews, focus group discussions and face-to-face intercultural dialogues. We design, validate and apply different instruments with questions adapted to the context and role of the participants, and recorded and transcribed the sessions and analyzed them in qualitative analysis software. We used the Consolidated Framework for Implementation Research (CFIR) to complement the above instrument questions, to guide data analysis, and apply the Consolidated Criteria for Reporting Qualitative Research (COREQ).
      Results: Records of 159 participants were included; 21 individual and 3 group interviews, 6 focus group discussions and 4 intercultural dialogues were carried out. 21 strong, 30 weak, 6 neutral barriers as well as 5 weak and 11 strong facilitators were identified. 62% of the strong barriers and 40% of the weak ones were concentrated in the "Outer Setting Domain". Only 16 facilitators were identified, 44% in the "Innovation" domain.
      Conclusions: Multiple political, administrative, geographical, logistical and cultural access barriers, as well as external and internal migration of the population, explain low coverage in mass administration of azithromycin and albendazole. It is necessary to review them individually to implement an improvement plan that also recognizes the identified facilitators.
      Competing Interests: The authors have declared that no competing interests exist.
      (Copyright: © 2024 Trujillo-Trujillo et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
    • References:
      PLoS Negl Trop Dis. 2018 Feb 26;12(2):e0006288. (PMID: 29481558)
      Implement Sci. 2022 Oct 29;17(1):75. (PMID: 36309746)
      Implement Sci. 2009 Aug 07;4:50. (PMID: 19664226)
      Glob Health Res Policy. 2022 Dec 2;7(1):47. (PMID: 36461087)
      PLoS Negl Trop Dis. 2022 Jun 27;16(6):e0010169. (PMID: 35759466)
      Int J Qual Health Care. 2007 Dec;19(6):349-57. (PMID: 17872937)
      Trans R Soc Trop Med Hyg. 2011 Dec;105(12):683-93. (PMID: 22040463)
      J Antimicrob Chemother. 2014 Sep;69(9):2376-82. (PMID: 24894419)
      BMJ Glob Health. 2021 Aug;6(8):. (PMID: 34385158)
      PLoS Negl Trop Dis. 2020 Jul 17;14(7):e0007613. (PMID: 32678821)
      Singapore Med J. 2008 Mar;49(3):256-60; quiz 261. (PMID: 18363011)
      Glob Health Action. 2019;12(1):1570646. (PMID: 30773102)
      Sex Transm Infect. 2019 Nov;95(7):522-528. (PMID: 30981999)
      Trop Med Int Health. 2005 Aug;10(8):764-72. (PMID: 16045463)
      Qual Health Res. 2019 Aug;29(10):1483-1496. (PMID: 30628545)
      Emerg Infect Dis. 2017 May;23(5):809-812. (PMID: 28418319)
    • الرقم المعرف:
      83905-01-5 (Azithromycin)
      F4216019LN (Albendazole)
      0 (Anthelmintics)
      0 (Anti-Bacterial Agents)
    • الموضوع:
      Date Created: 20241211 Date Completed: 20241211 Latest Revision: 20241213
    • الموضوع:
      20250114
    • الرقم المعرف:
      PMC11633981
    • الرقم المعرف:
      10.1371/journal.pone.0310143
    • الرقم المعرف:
      39661584